Physician profile
Kevin Watson
NPI 1205891280
$3,160.05
in general payments reported to CMS, 2019-2025
23 companies · $492 in 2025
The $492 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $104 · 2021: $545 · 2022: $910 · 2023: $412 · 2024: $415 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.44 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,728.13 | 2019-2025 | Trelegy Ellipta, Nucala |
| Novartis Pharmaceuticals Corporation | $274.22 | 2020-2023 | |
| Genentech USA, INC. | $137.54 | 2021-2024 | Xolair, Esbriet |
| Harmony Biosciences LLC | $133.78 | 2021-2023 | Wakix |
| Grifols USA, LLC | $124.46 | 2019 | |
| Mallinckrodt Hospital Products INC. | $112.18 | 2022-2024 | Acthar |
| Insmed, INC. | $90.16 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $80.00 | 2022 | |
| Amgen INC. | $64.73 | 2024-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $58.95 | 2019-2022 | |
| Zoll Respicardia, INC. | $54.35 | 2024 | Remede System |
| Csl Behring | $48.15 | 2019-2022 | |
| Pulmonx Corporation | $39.95 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Shire North American Group INC | $33.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.94 | 2023 | Hyqvia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.98 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.98 | 2021 | |
| Mylan Specialty L.P. | $18.55 | 2019 | |
| Eisai INC. | $18.04 | 2022 | |
| Merck Sharp & Dohme LLC | $17.99 | 2021 | |
| Pfizer INC. | $17.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.88 | 2019 | |
| Philips North America LLC | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.